The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass
NCT ID: NCT01843881
Last Updated: 2013-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
EARLY_PHASE1
20 participants
INTERVENTIONAL
2012-03-31
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exendin 9, 39
Exendin 9, 39 will be infused at 300pmol/kg/min in either first intervention period or second intervention period.
Exendin 9, 39
Exendin 9,39 is a competitive antagonist of endogenous GLP-1.
Placebo
A saline infusion will be administered in either first intervention period or second intervention period.
Placebo
A saline infusion will be given to match the study drug infusion.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exendin 9, 39
Exendin 9,39 is a competitive antagonist of endogenous GLP-1.
Placebo
A saline infusion will be given to match the study drug infusion.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must match RYGB subjects in age, weight, and gender
* Subjects will be without active systemic illness
Exclusion Criteria
* For Female Subjects: positive pregnancy text at the time of enrollment or study
* Subjects with functional or organic bowel symptoms.
20 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
National Center for Research Resources (NCRR)
NIH
Adrian Vella
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Adrian Vella
Consultant, Endocrinology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adrian Vella, M.D.
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic
Rochester, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.